Valvular & structural heart disease
Three-Year Outcomes Following Transcatheter Aortic Valve Replacement (TAVR) in Younger (<75 Years) Low-Surgical-Risk Severe Aortic Stenosis Patients
Authors' conclusion
Low-risk patients <75 years treated with supra-annular, self-expanding TAVR had comparable 3-year all-cause mortality and lower disabling stroke compared with patients treated with surgery. There was significantly better valve performance in patients treated with TAVR.
Study context
- Population
- Low-surgical-risk patients aged <75 years with severe AStrial randomised 1414
- Participants
- 352 vs 351
- Comparison
- Supra-annular, self-expanding TAVR vs surgery
- TAVRn = 352
- Surgeryn = 351reference
- Primary endpoint
- All-cause mortality or disabling stroke
- Follow-up
- 3 years
Methodological detailssubgroup aged <75 years
- Subgroup aged <75 years
Primary result
As reported in the abstract
P = 0.241
Further findings
Disabling stroke · 3 years
P = 0.019
All-cause mortality · 3 years
- No difference between TAVR and surgery
Valve performance: mean aortic gradient, severe prosthesis-patient mismatch · 3 years
- Lower mean aortic gradients with TAVR
- P < 0.001
- Lower severe prosthesis-patient mismatch with TAVR
- P < 0.001
Residual ≥moderate paravalvular regurgitation · 3 years
- No significant differences
Safety
Pacemaker implantation · 3 years
P < 0.001
Valve reintervention · 3 years
P = 0.962
Valve thrombosis and endocarditis · 3 years
- Similar between groups
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →